Loading
A phase 1/2 trial of Carboplatin, Nedaplatin, Niraparib, Bevacizumab and Toripalimab in advanced solid tumours, run by Wigen Biomedicine Technology (Shanghai) Co., Ltd., now recruiting.
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06953323 by Wigen Biomedicine Technology (Shanghai) Co., Ltd., with 86 participants planned, started 2025-07-10 and due to reach its primary completion in 2029-06-30. Interventions recorded: WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin, WJB001 Capsules+Paclitaxel+carboplatin, WJB001 Capsules+Niraparib, WJB001 Capsules+Bevacizumab and WJB001 Capsules+JS207/JS001.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares WJB001, Wigen Biomedicine Technology (Shanghai), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Niraparib, Toripalimab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Niraparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/